Jun Seoung Wook, Kim Min-Soo, Kim Jeong-Soo, Park Hee Jun, Lee Sibeum, Woo Jong-Soo, Hwang Sung-Joo
College of Pharmacy, Chungnam National University, Daejeon, Republic of Korea.
Eur J Pharm Biopharm. 2007 Jun;66(3):413-21. doi: 10.1016/j.ejpb.2006.11.013. Epub 2006 Nov 29.
In the present study, the practically insoluble drug, simvastatin (SV), and its inclusion complex with hydroxypropyl beta-cyclodextrin (HP-beta-CD) prepared using supercritical antisolvent (SAS) process were investigated to improve the aqueous solubility and the dissolution rate of drug, thus enhancing its bioavailability. Inclusion complexation in aqueous solution and solid state was evaluated by the phase solubility diagram, differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), Fourier-transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM). The phase solubility diagram with HP-beta-CD was classified as A(L)-type at all temperatures investigated, indicating the formation of 1:1 stoichiometric inclusion complex. The apparent complexation constants (K(1:1)) calculated from phase solubility diagram were 774, 846 and 924 M(-1) at 25, 37 and 45+/-0.5 degrees C, respectively. No endothermic and characteristic diffraction peaks corresponding to SV was observed for the inclusion complex in DSC and PXRD. FT-IR study demonstrated the presence of intermolecular hydrogen bonds between SV and HP-beta-CD in inclusion complex, resulting in the formation of amorphous form. Aqueous solubility and dissolution studies indicated that the dissolution rates were remarkably increased in inclusion complex, compared with the physical mixture and drug alone. Moreover, SV/HP-beta-CD inclusion complex performed better than SV in reducing total cholesterol and triglyceride levels. This could be primarily attributed to the improved solubility and dissolution associated with inclusion complex between drug and HP-beta-CD. In conclusion, SAS process could be a useful method for the preparation of the inclusion complex of drug with HP-beta-CD and its solubility, dissolution rate and hypolipidemic activity were significantly increased by complexation between SV and HP-beta-CD.
在本研究中,对实际不溶性药物辛伐他汀(SV)及其通过超临界抗溶剂(SAS)工艺制备的与羟丙基-β-环糊精(HP-β-CD)的包合物进行了研究,以提高药物的水溶性和溶出速率,从而提高其生物利用度。通过相溶解度图、差示扫描量热法(DSC)、粉末X射线衍射法(PXRD)、傅里叶变换红外光谱法(FT-IR)和扫描电子显微镜(SEM)对水溶液和固态中的包合络合进行了评估。在所有研究温度下,与HP-β-CD的相溶解度图均归类为A(L)型,表明形成了化学计量比为1:1的包合物。由相溶解度图计算得到的表观络合常数(K(1:1))在25、37和45±0.5℃时分别为774、846和924 M⁻¹。在DSC和PXRD中,未观察到包合物中对应于SV的吸热峰和特征衍射峰。FT-IR研究表明,包合物中SV与HP-β-CD之间存在分子间氢键,导致形成无定形形式。水溶性和溶出研究表明,与物理混合物和单独的药物相比,包合物中的溶出速率显著提高。此外,SV/HP-β-CD包合物在降低总胆固醇和甘油三酯水平方面比SV表现更好。这主要归因于药物与HP-β-CD之间的包合络合提高了溶解度和溶出度。总之,SAS工艺可能是制备药物与HP-β-CD包合物的一种有用方法,并且通过SV与HP-β-CD之间的络合,其溶解度、溶出速率和降血脂活性显著提高。